New patents and publicity for Pacific Edge
New patents and publicity for Pacific Edge
By Pam Graham
March 18 (BusinessDesk) - Pacific Edge, the
Dunedin-based developer of technology to detect cancer, says
it has new patents and its technology will soon feature in a
medical journal.
A patent filed in Japan as part of
its technology targeted to detect stomach cancer has been
granted, the NZX-listed company said in a statement.
The same technology has previously been patented in New Zealand, Australia, China and Europe.
Mexico has also granted a
patent to Pacific Edge for technology in the development of
one of the company’s future products Cxbladder
Predict.
The patents increase the company's intellectual property, its key asset, chief executive David Darling says.
A science paper describing the clinical
performance of its bladder cancer test Cxbladder Triage has
also been accepted by the medical journal BioMed Central,
which will showcase the technology to an international
audience.
Publication is expected later this
month.
Cxbladder Triage is due to be released in the US this year after its launch in New Zealand.
It's a non-invasive laboratory test, which allows clinicians to segregate patients who have presented with blood in the urine, an early indicator of possible bladder cancer, who have a low probability of having urothelial carcinoma.
The identification of these patients saves money because expensive tests are not needed. The publication of the paper in BMC will help the company reach both clinicians and executives in healthcare organisations.
The company
says laboratory through-put of its products is tracking to
expectations following an active direct sales and marketing
programme to clinicians and healthcare organisations.
Pacific Edge Diagnostics US has 12 sales
executives.
Shares in the company last traded at 68
cents, and have declined 20 percent so far this
year.
(BusinessDesk)